These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 28536352)

  • 1. Designing the Sniper: Improving Targeted Human Cytolytic Fusion Proteins for Anti-Cancer Therapy via Molecular Simulation.
    Bochicchio A; Jordaan S; Losasso V; Chetty S; Perera RC; Ippoliti E; Barth S; Carloni P
    Biomedicines; 2017 Feb; 5(1):. PubMed ID: 28536352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineered human angiogenin mutations in the placental ribonuclease inhibitor complex for anticancer therapy: Insights from enhanced sampling simulations.
    Cong X; Cremer C; Nachreiner T; Barth S; Carloni P
    Protein Sci; 2016 Aug; 25(8):1451-60. PubMed ID: 27110669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel angiogenin mutants with increased cytotoxicity enhance the depletion of pro-inflammatory macrophages and leukemia cells ex vivo.
    Cremer C; Braun H; Mladenov R; Schenke L; Cong X; Jost E; Brümmendorf TH; Fischer R; Carloni P; Barth S; Nachreiner T
    Cancer Immunol Immunother; 2015 Dec; 64(12):1575-86. PubMed ID: 26472728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Granzyme M as a novel effector molecule for human cytolytic fusion proteins: CD64-specific cytotoxicity of Gm-H22(scFv) against leukemic cells.
    Schiffer S; Letzian S; Jost E; Mladenov R; Hristodorov D; Huhn M; Fischer R; Barth S; Thepen T
    Cancer Lett; 2013 Dec; 341(2):178-85. PubMed ID: 23973499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted human cytolytic fusion proteins at the cutting edge: harnessing the apoptosis-inducing properties of human enzymes for the selective elimination of tumor cells.
    Mungra N; Jordaan S; Hlongwane P; Naran K; Chetty S; Barth S
    Oncotarget; 2019 Jan; 10(8):897-915. PubMed ID: 30783518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiogenin mutants as novel effector molecules for the generation of fusion proteins with increased cytotoxic potential.
    Cremer C; Vierbuchen T; Hein L; Fischer R; Barth S; Nachreiner T
    J Immunother; 2015 Apr; 38(3):85-95. PubMed ID: 25710248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human Granzyme B Based Targeted Cytolytic Fusion Proteins.
    Hlongwane P; Mungra N; Madheswaran S; Akinrinmade OA; Chetty S; Barth S
    Biomedicines; 2018 Jun; 6(2):. PubMed ID: 29925790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel fully-human cytolytic fusion protein based on granzyme B shows in vitro cytotoxicity and ex vivo binding to solid tumors overexpressing the epidermal growth factor receptor.
    Niesen J; Hehmann-Titt G; Woitok M; Fendel R; Barth S; Fischer R; Stein C
    Cancer Lett; 2016 May; 374(2):229-40. PubMed ID: 26912070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Updates in the Development of ImmunoRNases for the Selective Killing of Tumor Cells.
    Jordaan S; Akinrinmade OA; Nachreiner T; Cremer C; Naran K; Chetty S; Barth S
    Biomedicines; 2018 Mar; 6(1):. PubMed ID: 29510557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Granzyme B-based cytolytic fusion protein targeting EpCAM specifically kills triple negative breast cancer cells in vitro and inhibits tumor growth in a subcutaneous mouse tumor model.
    Amoury M; Kolberg K; Pham AT; Hristodorov D; Mladenov R; Di Fiore S; Helfrich W; Kiessling F; Fischer R; Pardo A; Thepen T; Hussain AF; Nachreiner T; Barth S
    Cancer Lett; 2016 Mar; 372(2):201-9. PubMed ID: 26806809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Macromolecular crowding: chemistry and physics meet biology (Ascona, Switzerland, 10-14 June 2012).
    Foffi G; Pastore A; Piazza F; Temussi PA
    Phys Biol; 2013 Aug; 10(4):040301. PubMed ID: 23912807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CSPG4: A Target for Selective Delivery of Human Cytolytic Fusion Proteins and TRAIL.
    Jordaan S; Chetty S; Mungra N; Koopmans I; van Bommel PE; Helfrich W; Barth S
    Biomedicines; 2017 Jun; 5(3):. PubMed ID: 28657611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elimination of different leukaemia subtypes using novel CD89-specific human cytolytic fusion proteins.
    Gresch G; Schenke L; Mladenov R; Zwirner S; Cremer C; Niesen J; Grieger E; Brümmendorf T; Jost E; Fischer R; Stockmeyer B; Barth S; Nachreiner T; Stein C
    Br J Haematol; 2018 Oct; 183(2):313-317. PubMed ID: 29048126
    [No Abstract]   [Full Text] [Related]  

  • 15. A novel approach for targeted elimination of CSPG4-positive triple-negative breast cancer cells using a MAP tau-based fusion protein.
    Amoury M; Mladenov R; Nachreiner T; Pham AT; Hristodorov D; Di Fiore S; Helfrich W; Pardo A; Fey G; Schwenkert M; Thepen T; Kiessling F; Hussain AF; Fischer R; Kolberg K; Barth S
    Int J Cancer; 2016 Aug; 139(4):916-27. PubMed ID: 27037627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Granzyme B-H22(scFv), a human immunotoxin targeting CD64 in acute myeloid leukemia of monocytic subtypes.
    Stahnke B; Thepen T; Stöcker M; Rosinke R; Jost E; Fischer R; Tur MK; Barth S
    Mol Cancer Ther; 2008 Sep; 7(9):2924-32. PubMed ID: 18790773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of an adapted granzyme B-based anti-CD30 cytolytic fusion protein against PI-9-positive classical Hodgkin lymphoma cells in a murine model.
    Schiffer S; Hansen HP; Hehmann-Titt G; Huhn M; Fischer R; Barth S; Thepen T
    Blood Cancer J; 2013 Mar; 3(3):e106. PubMed ID: 23524591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted ex vivo reduction of CD64-positive monocytes in chronic myelomonocytic leukemia and acute myelomonocytic leukemia using human granzyme B-based cytolytic fusion proteins.
    Schiffer S; Rosinke R; Jost E; Hehmann-Titt G; Huhn M; Melmer G; Barth S; Thepen T
    Int J Cancer; 2014 Sep; 135(6):1497-508. PubMed ID: 24523193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Restoration of DAP Kinase Tumor Suppressor Function: A Therapeutic Strategy to Selectively Induce Apoptosis in Cancer Cells Using Immunokinase Fusion Proteins.
    Tur MK; Daramola AK; Gattenlöhner S; Herling M; Chetty S; Barth S
    Biomedicines; 2017 Oct; 5(4):. PubMed ID: 28976934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel PSCA targeting scFv-fusion proteins for diagnosis and immunotherapy of prostate cancer.
    Kessler C; Pardo A; Tur MK; Gattenlöhner S; Fischer R; Kolberg K; Barth S
    J Cancer Res Clin Oncol; 2017 Oct; 143(10):2025-2038. PubMed ID: 28667390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.